GlassScriptPhysician profile
Faozan Narvel
NPI 1215901020
$16,174.00
in general payments reported to CMS, 2019-2025
60 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,754 · 2020: $1,895 · 2021: $2,262 · 2022: $2,822 · 2023: $2,096 · 2024: $2,456 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,441.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,593.90 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,858.79 | 2021-2025 | |
| Lilly USA, LLC | $1,358.84 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $872.52 | 2019-2025 | Ozempic |
| Amgen INC. | $796.72 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $763.49 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Astellas Pharma US INC | $590.33 | 2019-2025 | Veozah |
| Abbott Laboratories | $531.71 | 2020-2025 | Freestyle Libre 3 |
| Pfizer INC. | $524.57 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $521.18 | 2019-2023 | Verquvo, Belsomra, Steglujan |
| Sanofi-Aventis U.S. LLC | $470.69 | 2019-2023 | |
| Glaxosmithkline, LLC. | $421.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $410.23 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $403.91 | 2021-2024 | |
| Amarin Pharma, INC. | $351.58 | 2019-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faozan Narvel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.